Login to Your Account

Analyst: 'Minimal' Threat to Amgen

Disappointing Safety Data Rock Affymax; Hematide Path Unclear

By Jennifer Boggs

Tuesday, June 22, 2010
Investors hoping for a home run with the much-anticipated Phase III data of Hematide in chronic renal failure patients - including shareholders who jumped aboard Affymax Inc. in an oversold $70 million offering late last year - were sorely disappointed. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription